Cumberland Pharmaceuticals Inc. (CPIX)
CPIX trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1087294/000108729426000020/0001087294-26-000020-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | CPIX on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | 2009 |
| SEC CIK | 0001087294 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | TN |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $44.5M |
| Net income | -$2.8M |
| Operating income | -$2.8M |
| Net margin | -6.4% |
| Operating margin | -6.3% |
| Revenue growth | +17.6% |
| Cash | $11.4M |
| Total assets | $76.8M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 1.8× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-11-13 |
| Cash and burn | $3.9M cash; operating cash flow $186K a quarter. | Report 2026-06-30 |
| Shares outstanding | 14,995,547 (2026-11-11); 14,956,627 a year earlier; 14,255,700 three years earlier. | Cover page 2026-11-11 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Carr, Riggs & Ingram LLC, Nashville, Tennessee, United States | PCAOB Form AP 2026-03-09 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q2 2026 2026-06-30 | $166K | -$4.3M | $169K | $3.9M | No debt tags | $31.3M | 10-Q 2026-08-07 |
| Q1 2026 2026-03-31 | $9.1M | -$3.3M | $387K | $11.0M | No debt tags | $31.5M | 10-Q 2026-05-08 |
| Q4 2025 2025-12-31 | $13.7M | -$1.4M | $3K | $11.4M | $0 | $34.1M | 10-K 2026-03-09 |
| Q3 2025 2025-09-30 | $8.3M | -$1.9M | $187K | $15.2M | No debt tags | $30.8M | 10-K 2026-03-09 |
| Q2 2025 2025-06-30 | $381K | -$741K | $844K | $16.1M | No debt tags | $31.6M | 10-Q 2026-08-07 |
| Q1 2025 2025-03-31 | $11.7M | $1.3M | $3.9M | $15.1M | No debt tags | $41.1M | 10-Q 2026-05-08 |
| Q4 2024 2024-12-31 | $10.4M | -$1.9M | $1.9M | $18.0M | $5.1M | $37.9M | 10-K 2026-03-09 |
| Q3 2024 2024-09-30 | $9.1M | -$1.5M | $476K | $17.5M | No debt tags | $36.8M | 10-K 2026-03-09 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2025-02-14 |
| Latest annual report | 10-K | 2026-03-09 |
| Latest quarterly / interim | 10-Q | 2026-11-13 |
| Latest current report | 8-K/A | 2026-11-16 |
| Latest proxy | DEFM14A | 2026-05-26 |
Source: SEC EDGAR submissions feed, 1,003 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +12.6% |
| 1 month | -18.0% |
| 3 months | -25.6% |
| Year to date | +47.7% |
| 1 year | +181.3% |
| From 52-week high | -34.4% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| RANI | Rani Therapeutics Holdings Inc. | $0.5403 | +2.66% | $75.4M |
| KALA | KALA BIO Inc. | $3.83 | -8.02% | $74.1M |
| TLSA | Tiziana Life Sciences Ltd. Common Shares | $0.5762 | +1.11% | $73.3M |
| PLYX | Polaryx Therapeutics Inc. | $1.67 | -6.99% | $83.2M |
| VTVT | vTv Therapeutics Inc. | $17.69 | -10.16% | $71.0M |
| RLYB | Rallybio Corporation | $15.43 | -1.88% | $86.4M |
| COYA | Coya Therapeutics Inc. | $3.00 | -4.15% | $70.4M |
| NKTX | Nkarta Inc. | $1.21 | +1.68% | $86.8M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier